Hims stock surged Wednesday, nearing a buy point, after the telehealth behemoth announced a menopause care program.
The move is largely expected after Hims & Hers Health (HIMS) unveiled a testosterone replacement launch last month, Leerink Partners analyst Michael Cherny said in a report.
“It is a logical extension of both the Hers brand and the recent (hormone replacement therapy) market entry,” he said. “We expect the push into menopause to help the Hers business surpass $1 (billion) in revenues in 2026.”
In afternoon trades, Hims stock popped 7.1% to 57.87. Shares rank No. 17 on the IBD 50 list of elite growth stocks. Hims stock is nearing a buy point at 60.55 out of a cup-with-handle base, MarketSurge chart analysis shows.
Hims Stock: Expanding Beyond Weight Loss
Hims & Hers is best-known for its weight-loss offerings, including compounded semaglutide and branded Zepbound. Semaglutide is the chemical backbone behind Novo Nordisk‘s (NVO) Wegovy, while Zepbound is Eli Lilly‘s (LLY) branded obesity treatment.
Cherny says moving into therapy areas “that are not weight-loss related is an incremental positive as it shows the reach of the platform beyond what has been the dominant weight loss topic.” The company will soon begin offering personalized treatment plans for woman with perimenopause and menopause, including estradiol and progesterone treatments in pills, patches and creams.
The menopause space is competitive, however, says Cherny.
“Like with any competition, the push and pull of personalization vs. cost vs. insurance coverage will factor into adoption/growth as well,” he said.
Hims & Hers expects adding the menopause offering will help the Hers business top $1 billion in sales this year. The company says it has more than half a million subscribers on Hers today. The Hers side of the business also offers weight loss and hair treatment, among other services.
Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.
YOU MAY ALSO LIKE:
Why Spruce Biosciences Just Skyrocketed Almost 1,400%
S&P 500 Health Giant Abbott Labs Skids On Mixed Report. But One Segment Shined.
Looking For The Next Big Stock Market Winners? Start With These 3 Steps
Options Trading: How To Start Using Options, How To Manage Risk
Source link
